Africa’s Health Sovereignty Agenda: What It Means for European Healthcare Companies

Africa’s healthcare systems are entering a new phase. For many years, several countries across the continent have relied heavily on imported medicines, externally financed programmes and international supply chains for essential health products. While these partnerships have contributed significantly to healthcare access, recent global disruptions have highlighted the vulnerability of systems that depend too heavily on external production and procurement.

Today, the discussion is increasingly focused on health sovereignty: the ability of African countries to secure essential medicines, diagnostics, vaccines and medical technologies while strengthening local capacity, institutional resilience and long-term sustainability. This ambition has recently become more explicit. In February 2026, African leaders adopted a Presidential Declaration on advancing local manufacturing of health products, reaffirming the continental objective of meeting at least 60% of Africa’s health product needs through local manufacturing by 2040. The declaration identifies pharmaceuticals, vaccines, diagnostics and medical devices as strategic priorities, while calling for stronger procurement mechanisms, financing, skills development, technology transfer and regulatory coordination. [1]

Africa CDC has further positioned this objective within the broader Africa Health Security and Sovereignty Agenda, which is built around governance, preparedness, financing, digital innovation and local manufacturing. In its April 2026 communication, Africa CDC linked the agenda directly to reduced external aid, recurring disease outbreaks and fragile global supply chains, recognising that healthcare resilience depends not only on access to products, but also on the capacity to produce, finance, regulate and deploy them effectively. [2] Health sovereignty should not be interpreted as an attempt to reduce international cooperation. African countries will continue to work with international companies, investors, universities and institutions. However, the nature of those partnerships is changing.

The most relevant opportunities will increasingly involve companies able to support local manufacturing, packaging, quality-control systems, regulatory readiness, workforce training, digital health implementation and reliable distribution. Rather than exporting a finished product with limited local involvement, companies may need to consider models based on technology transfer, local assembly, regional procurement, joint implementation or long-term institutional partnerships. This direction is consistent with the World Health Organization’s approach. Following the third World Local Production Forum in 2025, WHO reaffirmed that local production and technology transfer are central to improving access to quality-assured health products, reinforcing health security and supporting more sustainable healthcare systems. [3]

For European companies, this does not represent a retreat from African markets. On the contrary, it creates a broader and potentially more durable opportunity: contributing expertise, technology and validated processes to healthcare ecosystems that are actively seeking credible long-term partners. The transition from policy ambition to practical implementation is already visible. On 12 May 2026, Africa CDC announced the results of the first tender under the African Pooled Procurement Mechanism, focused on essential reproductive, maternal and newborn health medicines. The tender covered ten priority products across ten African Union Member States and, according to Africa CDC, achieved prices between 30% and 90% lower than individual Member State benchmarks. Five of the ten product categories involved African manufacturers. [4]

This development matters because pooled procurement can reshape the commercial environment for healthcare suppliers. Larger and more predictable purchasing mechanisms may make it easier for qualified manufacturers and technology providers to justify investments, strengthen supply continuity and develop partnerships across regional markets rather than approaching each country in isolation. These developments suggest that African healthcare markets are increasingly being organised around supply reliability, quality assurance, regional demand aggregation and locally anchored capacity.

The health sovereignty agenda is relevant far beyond vaccine or pharmaceutical manufacturing. It opens space for European companies active in generic medicines, hospital products, medical devices, diagnostic systems, laboratory equipment, pharmaceutical packaging, cold-chain logistics, quality-control infrastructure, GMP consulting and healthcare training. Digital health is also becoming increasingly relevant. Africa CDC has positioned digital innovation as one of the central pillars of health sovereignty, recognising that stronger healthcare systems require not only products and factories, but also better data management, connected facilities, digital triage, telemedicine and technology-enabled decision-making. [2]

This means that European medtech and digital health companies may have opportunities to participate in healthcare system development through solutions that are adapted to local clinical, operational and regulatory conditions. A hospital software platform, diagnostic device or telemedicine service designed for a European setting may still require substantial adaptation in terms of connectivity, training, maintenance, interoperability, affordability and institutional integration.

European institutions are already involved in strengthening African pharmaceutical and health-technology capacity. Through the Team Europe Initiative on Manufacturing and Access to Vaccines, Medicines and Health Technologies in Africa, known as MAV+, the European Union supports local pharmaceutical systems, manufacturing capacity, regulatory development, supply chains, research, skills and access to finance. The initiative is aligned with African strategies and forms part of the wider Global Gateway framework. [5] A recent example is the financing package announced on 16 April 2026 by the European Investment Bank, the European Commission and the International Finance Corporation in support of Biovac in South Africa. The initiative is intended to support the development of what the institutions describe as Africa’s first end-to-end multi-vaccine manufacturing facility, strengthening vaccine self-reliance and continental health security. [6]

For European companies, this broader institutional context may facilitate cooperation models that combine technology, industrial expertise, local partners and development-oriented financing. Despite the opportunities, healthcare is not a sector in which companies can improvise. African markets are diverse, and each country has its own regulatory pathways, procurement structures, clinical priorities, affordability constraints and institutional relationships. A healthcare solution that succeeds in Europe may require changes in pricing, packaging, product stability, distribution, maintenance, training or regulatory documentation before it can operate effectively in an African market. Trust is equally important. Hospitals, ministries, regulators and local distributors need confidence that international partners can deliver consistently, comply with local standards and remain committed beyond an initial commercial transaction.

A Quo Group supports pharmaceutical, medtech and digital health companies by connecting strategic analysis with practical market-entry execution. We help clients assess local demand, identify credible partners, understand regulatory and institutional pathways, evaluate partnership models and structure realistic pilots or implementation strategies. Africa’s health sovereignty agenda is creating meaningful opportunities for European companies prepared to think beyond transactional sales. The strongest partnerships will be those built around reliability, quality, training, technology transfer and shared value. Companies that enter early, with the right local understanding and credible partners, may become part of the next generation of African healthcare systems.